Basit öğe kaydını göster

dc.contributor.advisorÜNAL ÇEVİK, IŞIN
dc.contributor.authorZakharova, Nishana
dc.date.accessioned2023-08-04T11:34:59Z
dc.date.issued2023-06
dc.date.submitted2023-06-14
dc.identifier.citation1. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210. 2. Arnold M. Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia. 2018;38(1):1-211. 3. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population‐based study. Headache: The Journal of Head and Face Pain. 2008;48(8):1157-68. 4. Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489-96. 5. Mínguez-Olaondo A, Quintas S, Morollón Sánchez-Mateos N, López-Bravo A, Vila-Pueyo M, Grozeva V, et al. Cutaneous allodynia in migraine: a narrative review. Frontiers in Neurology. 2022;12:831035. 6. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17(11):954-76. 7. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. The journal of headache and pain. 2019;20(1):1-11. 8. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. 9. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563-78. 10. Rattanawong W, Rapoport A, Srikiatkhachorn A. Neurobiology of migraine progression. Neurobiology of Pain. 2022:100094. 11. Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609. 12. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559-66. 13. Westergaard ML, Glumer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain. 2014;155(10):2005-13. 14. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837-50. 15. Schwedt TJ, Hentz JG, Sahai‐Srivastava S, Spare NM, Martin VT, Treppendahl C, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross‐sectional observations from the Medication Overuse Treatment Strategy trial. Headache: The Journal of Head and Face Pain. 2021;61(2):351-62. 16. Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. The journal of headache and pain. 2018;19(1):1-9. 17. Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71(11):848-55. 18. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache: The Journal of Head and Face Pain. 2009;49(4):498-508. 9. Manack A, Buse D, Serrano D, Turkel C, Lipton R. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76(8):711-8. 20. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. 21. Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020;40(5):503-16. 22. Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A. The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS drugs. 2021;35(5):545-65. 23. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Annals of neurology. 2008;63(2):148-58. 24. Lovati C, D'Amico D, Rosa S, Suardelli M, Mailland E, Bertora P, et al. Allodynia in different forms of migraine. Neurological Sciences. 2007;28:S220-S1. 25. Goadsby P, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1990;28(2):183-7. 26. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. The journal of pain. 2009;10(9):895-926. 27. Ashkenazi A, Sholtzow M, Shaw J, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia. 2007;27(2):111-7. 28. Su M, Ran Y, Han X, Liu Y, Zhang X, Tan Q, et al. Rizatriptan overuse promotes hyperalgesia induced by dural inflammatory stimulation in rats by modulation of the serotonin system. European Journal of Neuroscience. 2016;44(4):2129-38. 29. Edvinsson J, Warfvinge K, Edvinsson L. Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study. The Journal of Headache and Pain. 2015;16(1):1-11. 30. Olesen J. International classification of headache disorders. The Lancet Neurology. 2018;17(5):396-7. 31. Lipton R, Schwedt T, Friedman B. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602. 32. Diener H-C, Limmroth V. Medication-overuse headache: a worldwide problem. The Lancet Neurology. 2004;3(8):475-83. 33. Dowson AJ, Dodick DW, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs. 2005;19(6):483-97. 34. Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, et al. Medication overuse headache. Nature Reviews Disease Primers. 2023;9(1):5. 35. Grazzi L, Andrasik F. Medication-overuse headache: description, treatment, and relapse prevention. Curr Pain Headache Rep. 2006;10(1):71-7. 36. Chen PK, Wang SJ. Medication Overuse and Medication Overuse Headache: Risk Factors, Comorbidities, Associated Burdens and Nonpharmacologic and Pharmacologic Treatment Approaches. Curr Pain Headache Rep. 2019;23(8):60. 37. Saper JR, Da Silva AN. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs. 2013;27(11):867-77. 38. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. European journal of neurology. 2012;19(5):703-11. 39. Westergaard ML, Glumer C, Hansen EH, Jensen RH. Medication overuse, healthy lifestyle behaviour and stress in chronic headache: Results from a population-based representative survey. Cephalalgia. 2016;36(1):15-28. 40. Lauwerier E, Paemeleire K, Van Damme S, Goubert L, Crombez G. Medication use in patients with migraine and medication-overuse headache: the role of problem-solving and attitudes about pain medication. Pain. 2011;152(6):1334-9. 41. Katsarava Z, Diener HC, Limmroth V. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf. 2001;24(12):921-7. 42. Rapoport AM. Medication overuse headache: awareness, detection and treatment. CNS Drugs. 2008;22(12):995-1004. 43. Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: A systematic review. Cephalalgia. 2016;36(4):371-86. 44. Radat F, Creac'h C, Swendsen JD, Lafittau M, Irachabal S, Dousset V, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia. 2005;25(7):519-22. 45. Radat F, Lanteri-Minet M. What is the role of dependence-related behavior in medication-overuse headache? Headache. 2010;50(10):1597-611. 46. Sarchielli P, Corbelli I, Messina P, Cupini LM, Bernardi G, Bono G, et al. Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study. Eur J Neurol. 2016;23(1):85-91. 47. Bigal ME, Lipton RB, Winner P, Reed M, Diamond S, Stewart WF. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007;69(1):16-25. 48. Organization WH. Headache disorders. 2016. Avaialble online at: https://www who int/news-room/fact-sheets/detail/headache-disorders. 2018. 49. Gelfand AA, Goadsby PJ, Allen IE. The relationship between migraine and infant colic: a systematic review and meta-analysis. Cephalalgia. 2015;35(1):63-72. 50. Wöber C, Wöber-Bingöl Ç, Uluduz D, Aslan TS, Uygunoglu U, Tüfekçi A, et al. Undifferentiated headache: broadening the approach to headache in children and adolescents, with supporting evidence from a nationwide school-based cross-sectional survey in Turkey. The journal of headache and pain. 2018;19:1-9. 51. Manandhar K, Risal A, Steiner TJ, Holen A, Linde M. The prevalence of primary headache disorders in Nepal: a nationwide population-based study. The journal of headache and pain. 2015;16(1):1-10. 52. Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJ, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163(2):e293-e309. 53. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):459-80. 54. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache: The Journal of Head and Face Pain. 2018;58(5):700-14. 55. Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Adams AM, et al., editors. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clinic Proceedings; 2016: Elsevier. 56. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache: The Journal of Head and Face Pain. 2012;52(10):1456-70. 57. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache: The Journal of Head and Face Pain. 2005;45:S3-S13. 58. Blumenfeld A, Varon S, Wilcox T, Buse D, Kawata A, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301-15. 59. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache: The Journal of Head and Face Pain. 2015;55:103-22. 60. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-25. 61. ÖZGE A, DOMAÇ S, BAYKAL B, Uludüz D, BELEN H. Başağrısı Bozukluklarının uluslararası sınıflaması. 2021. 62. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain. 1996;119(2):355-61. 63. Petrusic I, Zidverc-Trajkovic J, Podgorac A, Sternic N. Underestimated phenomena: higher cortical dysfunctions during migraine aura. Cephalalgia. 2013;33(10):861-7. 64. Hansen JM, Goadsby PJ, Charles AC. Variability of clinical features in attacks of migraine with aura. Cephalalgia. 2016;36(3):216-24. 65. Karsan N, Prabhakar P, Goadsby P. Characterising the premonitory stage of migraine in children: a clinic-based study of 100 patients in a specialist headache service. The journal of headache and pain. 2016;17:1-7. 66. Calhoun AH, Ford S, Millen C, Finkel AG, Truong Y, Nie Y. The prevalence of neck pain in migraine. Headache: The Journal of Head and Face Pain. 2010;50(8):1273-7. 67. Gori S, Lucchesi C, Baldacci F, Bonuccelli U. Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. Functional neurology. 2015;30(2):119. 68. Silberstein SD. Migraine symptoms: Results of a survey of self‐reported migraineurs. Headache: The Journal of Head and Face Pain. 1995;35(7):387-96. 69. Friedman DI, Evans RW. Are blurred vision and short-duration visual phenomena migraine aura symptoms. Headache. 2017;57(4):643-7. 70. Bigal M, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology. 2008;70(17):1525-33. 71. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine postdrome: an electronic diary study. Neurology. 2016;87(3):309-13. 72. Ducros A. Familial hemiplegic migraine: a model for the genetic studies of migraine. Sage Publications Sage UK: London, England; 2014. p. 1035-7. 73. Society HCCotIH. The international classification of headache disorders, (beta version). Cephalalgia. 2013;33(9):629-808. 74. Goadsby PJ, Holland PR. An Update: Pathophysiology of Migraine. Neurologic clinics. 2019;37(4):651-71. 75. Santoro G, Bernasconi F, Sessa F, Venco A. Premonitory symptoms in migraine without aura: a clinical investigation. Functional neurology. 1990;5(4):339-44. 76. Quintela E, Castillo J, Munoz P, Pascual J. Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia. 2006;26(9):1051-60. 77. Giffin N, Ruggiero L, Lipton RB, Silberstein S, Tvedskov J, Olesen J, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60(6):935-40. 78. Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(1):232-41. 79. Karsan N, Bose P, Goadsby PJ. The migraine premonitory phase. CONTINUUM: Lifelong Learning in Neurology. 2018;24(4):996-1008. 80. Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches: CME. Headache: The Journal of Head and Face Pain. 2007;47(6):951-62. 81. Holland PR, Bartsch T. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28(7):681-2. 82. Martins-Oliveira M, Tavares I, Goadsby PJ. Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. Brain research. 2021;1770:147629. 83. Oliveira M-M, Akerman S, Tavares I, Goadsby PJ. Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. Pain. 2016;157(8):1666. 84. Charbit AR, Akerman S, Goadsby PJ. Dopamine: what's new in migraine? Current opinion in neurology. 2010;23(3):275-81. 85. Charbit AR, Akerman S, Holland PR, Goadsby PJ. Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. Journal of Neuroscience. 2009;29(40):12532-41. 86. Serra G, Collu M, Loddo S, Celasco G, Gessa G. Hypophysectomy prevents yawning and penile erection but not hypomotility induced by apomorphine. Pharmacology Biochemistry and Behavior. 1983;19(6):917-9. 87. Waelkens J. Domperidone in the prevention of complete classical migraine. British Medical Journal (Clinical research ed). 1982;284(6320):944. 88. Burstein R, Jakubowski M. Unitary hypothesis for multiple triggers of the pain and strain of migraine. Journal of comparative neurology. 2005;493(1):9-14. 89. Lampl C, Rudolph M, Deligianni CI, Mitsikostas DD. Neck pain in episodic migraine: premonitory symptom or part of the attack? The journal of headache and pain. 2015;16(1):1-5. 90. Goadsby PJ, Knight YE, Hoskin KL. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain. 1997;73(1):23-8. 91. Johnston MM, Jordan SE, Charles AC. Pain referral patterns of the C1 to C3 nerves: implications for headache disorders. Annals of neurology. 2013;74(1):145-8. 92. Gazerani P, Cairns BE. Dysautonomia in the pathogenesis of migraine. Expert review of neurotherapeutics. 2018;18(2):153-65. 93. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Archives of Neurology & Psychiatry. 1941;46(2):331-9. 94. Leao AA. Spreading depression of activity in the cerebral cortex. Journal of neurophysiology. 1944;7(6):359-90. 95. Hadjikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the national academy of sciences. 2001;98(8):4687-92. 96. Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiological reviews. 2001;81(3):1065-96. 97. Timm FP, Houle TT, Grabitz SD, Lihn A-L, Stokholm JB, Eikermann-Haerter K, et al. Migraine and risk of perioperative ischemic stroke and hospital readmission: hospital based registry study. bmj. 2017;356. 98. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiological reviews. 2017. 99. Bartsch T, Goadsby P. Anatomy and physiology of pain referral patterns in primary and cervicogenic headache disorders. Headache Currents. 2005;2(2):42-8. 100. Weiller C, May A, Limmroth Va, Jüptner M, Kaube H, Schayck R, et al. Brain stem activation in spontaneous human migraine attacks. Nature medicine. 1995;1(7):658-60. 101. Pozo-Rosich P, Storer R, Charbit A, Goadsby P. Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia. 2015;35(14):1298-307. 102. Zhang L, Lu C, Kang L, Li Y, Tang W, Zhao D, et al. Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup. The Journal of Headache and Pain. 2022;23(1):1-11. 103. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. Journal of Neuroscience. 2015;35(17):6619-29. 104. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130(1-2):166-76. 105. Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the trigeminal system in migraine. Headache: The Journal of Head and Face Pain. 2019;59(5):659-81. 106. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179-86. 107. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual review of pharmacology and toxicology. 2015;55:533-52. 108. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron–glia signaling in trigeminal ganglion: implications for migraine pathology. Headache: The Journal of Head and Face Pain. 2007;47(7):1008-23. 109. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews Neurology. 2010;6(10):573-82. 110. Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. Journal of Neuroscience. 2011;31(40):14204-17. 111. Noseda R, Borsook D, Burstein R. Neuropeptides and neurotransmitters that modulate thalamo‐cortical pathways relevant to migraine headache. Headache: The Journal of Head and Face Pain. 2017;57:97-111. 112. Burstein R, Jakubowski M, Garcia‐Nicas E, Kainz V, Bajwa Z, Hargreaves R, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Annals of neurology. 2010;68(1):81-91. 113. Suzuki K, Suzuki S, Shiina T, Kobayashi S, Hirata K. Central sensitization in migraine: a narrative review. Journal of Pain Research. 2022:2673-82. 114. Amin FM, Hougaard A, Magon S, Sprenger T, Wolfram F, Rostrup E, et al. Altered thalamic connectivity during spontaneous attacks of migraine without aura: a resting-state fMRI study. Cephalalgia. 2018;38(7):1237-44. 115. Puledda F, Shields K. Non-pharmacological approaches for migraine. Neurotherapeutics. 2018;15(2):336-45. 116. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1981;9(4):344-52. 117. Barral E, Martins Silva E, García-Azorín D, Viana M, Puledda F. Differential Diagnosis of Visual Phenomena Associated with Migraine: Spotlight on Aura and Visual Snow Syndrome. Diagnostics. 2023;13(2):252. 118. Messina R, Filippi M, Goadsby PJ. Recent advances in headache neuroimaging. Current opinion in neurology. 2018;31(4):379-85. 119. Dobrynina LA, Suslina AD, Gubanova MV, Belopasova AV, Sergeeva AN, Evers S, et al. White matter hyperintensity in different migraine subtypes. Scientific Reports. 2021;11(1):10881. 120. Ahmed SR, Mohamed AAM, Salem HH, Helmy S, Moustafa RR, Borham SMF. Association of white matter hyperintensities with migraine phenotypes and response to treatment. Acta Neurologica Belgica. 2022:1-9. 121. Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. The journal of headache and pain. 2020;21(1):1-16. 122. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache: The Journal of Head and Face Pain. 2006;46(9):1334-43. 123. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology. 2016;12(8):455-64. 124. Torres-Ferrús M, Ursitti F, Alpuente A, Brunello F, Chiappino D, de Vries T, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. The journal of headache and pain. 2020;21(1):1-12. 125. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(2 Suppl):S23-S34. 126. Hipolito Rodrigues M, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018;21(3):256-66. 127. Pakalnis A, editor Migraine and hormones. Seminars in Pediatric Neurology; 2016: Elsevier. 128. Lay CL, Broner SW. Migraine in women. Neurologic clinics. 2009;27(2):503-11. 129. Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Frontiers in neuroscience. 2015;9:37. 130. Ornello R, Caponnetto V, Frattale I, Sacco S. Patterns of migraine in postmenopausal women: a systematic review. Neuropsychiatric Disease and Treatment. 2021;17:859. 131. Nierenburg HdC, Ailani J, Malloy M, Siavoshi S, Hu NN, Yusuf N. Systematic review of preventive and acute treatment of menstrual migraine. Headache: The Journal of Head and Face Pain. 2015;55(8):1052-71. 132. Brandes JL. The influence of estrogen on migraine: a systematic review. Jama. 2006;295(15):1824-30. 133. Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache: The Journal of Head and Face Pain. 2018;58(1):5-21. 134. Lippi G, Mattiuzzi C. Cortisol and migraine: a systematic literature review. Agri. 2017;29(3):95-9. 135. Baksa D, Gecse K, Kumar S, Toth Z, Gal Z, Gonda X, et al. Circadian variation of migraine attack onset: a review of clinical studies. BioMed Research International. 2019;2019. 136. Spanou I, Bougea A, Liakakis G, Rizonaki K, Anagnostou E, Duntas L, et al. Relationship of Migraine and Tension‐Type Headache With Hypothyroidism: A Literature Review. Headache: The Journal of Head and Face Pain. 2019;59(8):1174-86. 137. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640-5. 138. Pavlovic JM, Vieira JR, Lipton RB, Bond DS. Association between obesity and migraine in women. Current pain and headache reports. 2017;21(10):1-6. 139. Peterlin BL, Sacco S, Bernecker C, Scher AI. Adipokines and migraine: a systematic review. Headache: The Journal of Head and Face Pain. 2016;56(4):622-44. 140. Rainero I, Govone F, Gai A, Vacca A, Rubino E. Is migraine primarily a metaboloendocrine disorder? Current pain and headache reports. 2018;22(5):1-9. 141. Hosseinpour M, Maleki F, Khoramdad M, Sullman MJ, Nejadghaderi SA, Kolahi A-A, et al. A systematic literature review of observational studies of the bilateral association between diabetes and migraine. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(3):673-8. 142. Fagernaes C, Heuch I, Zwart JA, Winsvold B, Linde M, Hagen K. Blood pressure as a risk factor for headache and migraine: A prospective population‐based study. European Journal of Neurology. 2015;22(1):156-e11. 143. Scher A, Terwindt G, Picavet H, Verschuren W, Ferrari M, Launer L. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology. 2005;64(4):614-20. 144. Onderwater GL, Ligthart L, Bot M, Demirkan A, Fu J, van der Kallen CJ, et al. Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine. Neurology. 2019;92(16):e1899-e911. 145. Polderman TJ, Benyamin B, De Leeuw CA, Sullivan PF, Van Bochoven A, Visscher PM, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nature genetics. 2015;47(7):702-9. 146. Gormley P, Kurki MI, Hiekkala ME, Veerapen K, Häppölä P, Mitchell AA, et al. Common variant burden contributes to the familial aggregation of migraine in 1,589 families. Neuron. 2018;98(4):743-53. e4. 147. Ophoff RA, Terwindt GM, Vergouwe MN, Van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543-52. 148. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. The Lancet Neurology. 2015;14(1):65-80. 149. Anttila V, Winsvold BS, Gormley P, Kurth T, Bettella F, McMahon G, et al. Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nature genetics. 2013;45(8):912-7. 150. Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature genetics. 2016;48(8):856-66. 151. Eising E, A Datson N, van den Maagdenberg AM, Ferrari MD. Epigenetic mechanisms in migraine: a promising avenue? BMC medicine. 2013;11(1):1-6. 152. Gerring ZF, McRae AF, Montgomery GW, Nyholt DR. Genome-wide DNA methylation profiling in whole blood reveals epigenetic signatures associated with migraine. BMC genomics. 2018;19(1):1-10. 153. Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review. Cephalalgia. 2005;25(3):165-78. 154. Peroutka SJ. What turns on a migraine? A systematic review of migraine precipitating factors. Current pain and headache reports. 2014;18(10):1-6. 155. Dresler T, Caratozzolo S, Guldolf K, Huhn J-I, Loiacono C, Niiberg-Pikksööt T, et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. The journal of headache and pain. 2019;20:1-17. 156. Peterlin BL, Gupta S, Ward TN, MacGregor A. Sex matters: evaluating sex and gender in migraine and headache research. Wiley Online Library; 2011. p. 839-42. 157. Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B, et al. Male and female sex hormones in primary headaches. The journal of Headache and Pain. 2018;19:1-12. 158. Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, et al. Migraine and sleep disorders: a systematic review. The Journal of Headache and Pain. 2020;21(1):1-13. 159. Boardman HF, Thomas E, Millson DS, Croft P. Psychological, sleep, lifestyle, and comorbid associations with headache. Headache: The Journal of Head and Face Pain. 2005;45(6):657-69. 160. Mustelin L, Raevuori A, Kaprio J, Keski‐Rahkonen A. Association between eating disorders and migraine may be explained by major depression. International Journal of Eating Disorders. 2014;47(8):884-7. 161. Razeghi Jahromi S, Ghorbani Z, Martelletti P, Lampl C, Togha M, Federation SoASotEH. Association of diet and headache. The journal of Headache and Pain. 2019;20:1-11. 162. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. Bmj. 2009;339. 163. Lee MJ, Lee C, Chung C-S. The migraine–stroke connection. Journal of stroke. 2016;18(2):146. 164. Alqaqa A. The Association of cardiovascular disease and migraine: review. J Clini Exp Cardiol. 2016;7(8):465. 165. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache: The Journal of Head and Face Pain. 2018;58(4):496-505. 166. Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: a review. Cephalalgia. 2016;36(1):67-91. 167. Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web‐based survey. Headache: The Journal of Head and Face Pain. 2016;56(2):306-22. 168. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. Jama. 2003;290(18):2443-54. 169. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. Journal of the neurological sciences. 2017;372:307-15. 170. Robbins L. Precipitating factors in migraine: a retrospective review of 494 patients. Headache: The Journal of Head and Face Pain. 1994;34(4):214-6. 171. Zhang Q, Shao A, Jiang Z, Tsai H, Liu W. The exploration of mechanisms of comorbidity between migraine and depression. Journal of cellular and molecular medicine. 2019;23(7):4505-13. 172. Kim S-Y, Park S-P. The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. The journal of headache and pain. 2014;15(1):1-8. 173. Beghi E, Bussone G, D’Amico D, Cortelli P, Cevoli S, Manzoni GC, et al. Headache, anxiety and depressive disorders: the HADAS study. The journal of headache and pain. 2010;11:141-50. 174. Samaan Z, Farmer A, Craddock N, Jones L, Korszun A, Owen M, et al. Migraine in recurrent depression: case–control study. The British Journal of Psychiatry. 2009;194(4):350-4. 175. Baskin SM, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache: The Journal of Head and Face Pain. 2006;46:S76-S87. 176. Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatric comorbidities of episodic and chronic migraine. Journal of neurology. 2013;260:1960-9. 177. Mercante JP, Peres MF, Bernik MA. Primary headaches in patients with generalized anxiety disorder. The Journal of Headache and Pain. 2011;12:331-8. 178. Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P. Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. The journal of headache and pain. 2009;10:283-90. 179. Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache: The Journal of Head and Face Pain. 2012;52(1):3-17. 180. Scher A, Stewart W, Ricci J, Lipton R. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106(1-2):81-9. 181. Buse D, Manack A, Serrano D, Turkel C, Lipton R. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. Journal of Neurology, Neurosurgery & Psychiatry. 2010;81(4):428-32. 182. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache: The Journal of Head and Face Pain. 1987;27(2):102-6. 183. Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688-95. 184. He Z, Dong L, Zhang Y, Kong Q, Tan G, Zhou J. Metabolic syndrome in female migraine patients is associated with medication overuse headache: a clinic‐based study in China. European journal of neurology. 2015;22(8):1228-34. 185. Kitamura E, Kanazawa N, Hamada J. Hyperleptinemia increases the susceptibility of the cortex to generate cortical spreading depression. Cephalalgia. 2015;35(4):327-34. 186. Vieira D, Masruha M, Gonçalves A, Zukerman E, Senne Soares C, da Graça Naffah-Mazzacoratti M, et al. Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine. Cephalalgia. 2008;28(6):609-13. 187. De Simone R, Ranieri A. The role of intracranial hypertension in the chronification of migraine. Neurological Sciences. 2015;36:23-8. 188. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, et al. Depression and risk of transformation of episodic to chronic migraine. The journal of headache and pain. 2012;13:615-24. 189. Welch MK, Goadsby PJ. Chronic daily headache: nosology and pathophysiology. Current opinion in neurology. 2002;15(3):287-95. 190. Hovaguimian A, Roth J. Management of chronic migraine. bmj. 2022;379. 191. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: A randomized, placebo‐controlled trial of quality of life and other efficacy measures. Headache: The Journal of Head and Face Pain. 2009;49(8):1153-62. 192. Pascual J, Rivas M, Leira R. Testing the combination beta‐blocker plus topiramate in refractory migraine. Acta neurologica scandinavica. 2007;115(2):81-3. 193. Silberstein S, Dodick D, Lindblad A, Holroyd K, Harrington M, Mathew N, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976-84. 194. Costa C, Tozzi A, Rainero I, Cupini LM, Calabresi P, Ayata C, et al. Cortical spreading depression as a target for anti-migraine agents. The journal of headache and pain. 2013;14(1):1-18. 195. Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. Journal of Clinical Psychiatry. 2008;69(9):1449. 196. Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, et al. CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Current pain and headache reports. 2019;23:1-10. 197. Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. The Journal of Headache and Pain. 2021;22(1):1-9. 198. Tajti J, Szok D, Csáti A, Vécsei L. The pharmacotherapeutic management of episodic and chronic migraine with gepants. Expert Opinion on Pharmacotherapy. 2023;24(8):947-58. 199. Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803. 200. Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-14. 201. Hollanda L, Monteiro L, Melo A. Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. Neurology International. 2014;6(4):5133. 202. Tao H, Wang T, Dong X, Guo Q, Xu H, Wan Q. Effectiveness of transcutaneous electrical nerve stimulation for the treatment of migraine: a meta-analysis of randomized controlled trials. The journal of headache and pain. 2018;19(1):1-10. 203. Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894-904. 204. Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. Jama. 2019;322(19):1887-98. 205. Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ. Pathophysiology of medication overuse headache--an update. Headache. 2014;54(1):204-10. 206. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache: The Journal of head and face pain. 2003;43(3):179-90. 207. Roeckel L-A, Le Coz G-M, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience. 2016;338:160-82. 208. Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M. Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain. 2005;9(3):285-91. 209. Moskowitz MA. The neurobiology of vascular head pain. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1984;16(2):157-68. 210. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system—40 years and counting. The Lancet Neurology. 2019;18(8):795-804. 211. Ma W, Zheng W-H, Kar S, Quirion R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience. 2000;99(3):529-39. 212. Chatchaisak D, Srikiatkhachorn A, Maneesri-le Grand S, Govitrapong P, Chetsawang B. The role of calcitonin gene-related peptide on the increase in transient receptor potential vanilloid-1 levels in trigeminal ganglion and trigeminal nucleus caudalis activation of rat. Journal of chemical neuroanatomy. 2013;47:50-6. 213. Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 2010;30(9):1101-9. 214. Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F. Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia. 2014;34(8):594-604. 215. Wanasuntronwong A, Jansri U, Srikiatkhachorn A. Neural hyperactivity in the amygdala induced by chronic treatment of rats with analgesics may elucidate the mechanisms underlying psychiatric comorbidities associated with medication-overuse headache. BMC neuroscience. 2017;18(1):1-12. 216. Srikiatkhachorn A, Puangniyom S, Govitrapong P. Plasticity of 5‐HT2A serotonin receptor in patients with analgesic‐induced transformed migraine. Headache: The Journal of Head and Face Pain. 1998;38(7):534-9. 217. Ayzenberg I, Obermann M, Leineweber K, Franke L, Yoon MS, Diener HC, et al. Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain. 2008;9(2):109-12. 218. Hagen K, Vatten L, Stovner L, Zwart J, Krokstad S, Bovim G. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia. 2002;22(8):672-9. 219. Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012;13(4):281-90. 220. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies. Pain. 2012;153(1):56-61. 221. Diener H-C, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nature Reviews Neurology. 2016;12(10):575-83. 222. Wang Y-F, Yu C-C, Kuan AS, Chen S-P, Wang S-J. Association between suicidal risks and medication-overuse headache in chronic migraine: a cross-sectional study. The Journal of Headache and Pain. 2021;22(1):36. 223. Cargnin S, Viana M, Sances G, Tassorelli C, Terrazzino S. A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia. 2018;38(7):1361-73. 224. Thorlund K, Sun-Edelstein C, Druyts E, Kanters S, Ebrahim S, Bhambri R, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016;17(1):107. 225. Manzoni GC, Russo M, Taga A, Torelli P. Neurobiology of chronicization. Neurological Sciences. 2017;38(1):81-4. 226. Evers S, Jensen R, European Federation of Neurological S. Treatment of medication overuse headache--guideline of the EFNS headache panel. Eur J Neurol. 2011;18(9):1115-21. 227. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9(4):391-401. 228. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. 2017;377(22):2113-22. 229. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47(5):614-24. 230. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache: The Journal of Head and Face Pain. 2006;46:S182-S91. 231. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. pain. 2011;152(3):S2-S15. 232. Suzuki K, Haruyama Y, Kobashi G, Sairenchi T, Uchiyama K, Yamaguchi S, et al. Central sensitization in neurological, psychiatric, and pain disorders: a multicenter case-controlled study. Pain Research and Management. 2021;2021:1-8. 233. Nijs J, Torres-Cueco R, Van Wilgen P, Lluch Girbés E, Struyf F, Roussel N, et al. Applying modern pain neuroscience in clinical practice: criteria for the classification of central sensitization pain. Pain physician. 2014;17(5):447-57. 234. Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the central sensitization inventory: a systematic review. Pain Practice. 2018;18(4):544-54. 235. Starkweather AR, Heineman A, Storey S, Rubia G, Lyon DE, Greenspan J, et al. Methods to measure peripheral and central sensitization using quantitative sensory testing: A focus on individuals with low back pain. Applied Nursing Research. 2016;29:237-41. 236. Lee MC, Zambreanu L, Menon DK, Tracey I. Identifying brain activity specifically related to the maintenance and perceptual consequence of central sensitization in humans. Journal of Neuroscience. 2008;28(45):11642-9. 237. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature medicine. 2002;8(2):136-42. 238. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2004;55(1):19-26. 239. Fox AW, Davis RL. Migraine chronobiology. Headache: The Journal of Head and Face Pain. 1998;38(6):436-41. 240. Stankewitz A, Aderjan D, Eippert F, May A. Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. Journal of Neuroscience. 2011;31(6):1937-43. 241. Young WB, Richardson ES, Shukla P. Brush allodynia in hospitalized headache patients. Headache: The Journal of Head and Face Pain. 2005;45(8):999-1003. 242. LoPinto C, Young W, Ashkenazi A. Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia. 2006;26(7):852-6. 243. Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, et al. Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arquivos de neuro-psiquiatria. 2017;75:153-9. 244. Schwedt TJ, Krauss MJ, Frey K, Gereau IV RW. Episodic and chronic migraineurs are hypersensitive to thermal stimuli between migraine attacks. Cephalalgia. 2011;31(1):6-12. 245. Maleki N, Szabo E, Becerra L, Moulton E, Scrivani SJ, Burstein R, et al. Ictal and interictal brain activation in episodic migraine: neural basis for extent of allodynia. PloS one. 2021;16(1):e0244320. 246. Delussi M, Vecchio E, Libro G, Quitadamo S, De Tommaso M. Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC neurology. 2020;20:1-12. 247. Guven H, Cilliler AE, Comoglu SS. Cutaneous allodynia in patients with episodic migraine. Neurol Sci. 2013;34(8):1397-402. 248. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs. 2004;18(6):337-42. 249. Levy D, Jakubowski M, Burstein R, editors. Differential effects of sumatriptan on peripheral and central trigeminovascular neurons reveal site of action critical for terminating migraine. Cephalalgia; 2003: BLACKWELL PUBLISHING LTD 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND. 250. Lewis T. Experiments relating to cutaneous hyperalgesia and its spread through somatic nerves. Clin Sci. 1936;2:373-421. 251. LaMotte RH, Shain CN, Simone DA, Tsai E. Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. Journal of neurophysiology. 1991;66(1):190-211. 252. Kilo S, Schmelz M, Koltzenburg M, Handwerker H. Different patterns of hyperalgesia induced by experimental inflammation in human skin. Brain. 1994;117(2):385-96. 1. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210. 2. Arnold M. Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia. 2018;38(1):1-211. 3. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population‐based study. Headache: The Journal of Head and Face Pain. 2008;48(8):1157-68. 4. Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489-96. 5. Mínguez-Olaondo A, Quintas S, Morollón Sánchez-Mateos N, López-Bravo A, Vila-Pueyo M, Grozeva V, et al. Cutaneous allodynia in migraine: a narrative review. Frontiers in Neurology. 2022;12:831035. 6. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17(11):954-76. 7. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. The journal of headache and pain. 2019;20(1):1-11. 8. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. 9. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563-78. 10. Rattanawong W, Rapoport A, Srikiatkhachorn A. Neurobiology of migraine progression. Neurobiology of Pain. 2022:100094. 11. Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609. 12. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559-66. 13. Westergaard ML, Glumer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain. 2014;155(10):2005-13. 14. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837-50. 15. Schwedt TJ, Hentz JG, Sahai‐Srivastava S, Spare NM, Martin VT, Treppendahl C, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross‐sectional observations from the Medication Overuse Treatment Strategy trial. Headache: The Journal of Head and Face Pain. 2021;61(2):351-62. 16. Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. The journal of headache and pain. 2018;19(1):1-9. 17. Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71(11):848-55. 18. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache: The Journal of Head and Face Pain. 2009;49(4):498-508. 19. Manack A, Buse D, Serrano D, Turkel C, Lipton R. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76(8):711-8. 20. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. 21. Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020;40(5):503-16. 22. Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A. The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS drugs. 2021;35(5):545-65. 23. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Annals of neurology. 2008;63(2):148-58. 24. Lovati C, D'Amico D, Rosa S, Suardelli M, Mailland E, Bertora P, et al. Allodynia in different forms of migraine. Neurological Sciences. 2007;28:S220-S1. 25. Goadsby P, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1990;28(2):183-7. 26. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. The journal of pain. 2009;10(9):895-926. 27. Ashkenazi A, Sholtzow M, Shaw J, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia. 2007;27(2):111-7. 28. Su M, Ran Y, Han X, Liu Y, Zhang X, Tan Q, et al. Rizatriptan overuse promotes hyperalgesia induced by dural inflammatory stimulation in rats by modulation of the serotonin system. European Journal of Neuroscience. 2016;44(4):2129-38. 29. Edvinsson J, Warfvinge K, Edvinsson L. Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study. The Journal of Headache and Pain. 2015;16(1):1-11. 30. Olesen J. International classification of headache disorders. The Lancet Neurology. 2018;17(5):396-7. 31. Lipton R, Schwedt T, Friedman B. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602. 32. Diener H-C, Limmroth V. Medication-overuse headache: a worldwide problem. The Lancet Neurology. 2004;3(8):475-83. 33. Dowson AJ, Dodick DW, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs. 2005;19(6):483-97. 34. Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, et al. Medication overuse headache. Nature Reviews Disease Primers. 2023;9(1):5. 35. Grazzi L, Andrasik F. Medication-overuse headache: description, treatment, and relapse prevention. Curr Pain Headache Rep. 2006;10(1):71-7. 36. Chen PK, Wang SJ. Medication Overuse and Medication Overuse Headache: Risk Factors, Comorbidities, Associated Burdens and Nonpharmacologic and Pharmacologic Treatment Approaches. Curr Pain Headache Rep. 2019;23(8):60. 37. Saper JR, Da Silva AN. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs. 2013;27(11):867-77. 38. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. European journal of neurology. 2012;19(5):703-11. 39. Westergaard ML, Glumer C, Hansen EH, Jensen RH. Medication overuse, healthy lifestyle behaviour and stress in chronic headache: Results from a population-based representative survey. Cephalalgia. 2016;36(1):15-28. 40. Lauwerier E, Paemeleire K, Van Damme S, Goubert L, Crombez G. Medication use in patients with migraine and medication-overuse headache: the role of problem-solving and attitudes about pain medication. Pain. 2011;152(6):1334-9. 41. Katsarava Z, Diener HC, Limmroth V. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf. 2001;24(12):921-7. 42. Rapoport AM. Medication overuse headache: awareness, detection and treatment. CNS Drugs. 2008;22(12):995-1004. 43. Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: A systematic review. Cephalalgia. 2016;36(4):371-86. 44. Radat F, Creac'h C, Swendsen JD, Lafittau M, Irachabal S, Dousset V, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia. 2005;25(7):519-22. 45. Radat F, Lanteri-Minet M. What is the role of dependence-related behavior in medication-overuse headache? Headache. 2010;50(10):1597-611. 46. Sarchielli P, Corbelli I, Messina P, Cupini LM, Bernardi G, Bono G, et al. Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study. Eur J Neurol. 2016;23(1):85-91. 47. Bigal ME, Lipton RB, Winner P, Reed M, Diamond S, Stewart WF. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007;69(1):16-25. 48. Organization WH. Headache disorders. 2016. Avaialble online at: https://www who int/news-room/fact-sheets/detail/headache-disorders. 2018. 49. Gelfand AA, Goadsby PJ, Allen IE. The relationship between migraine and infant colic: a systematic review and meta-analysis. Cephalalgia. 2015;35(1):63-72. 50. Wöber C, Wöber-Bingöl Ç, Uluduz D, Aslan TS, Uygunoglu U, Tüfekçi A, et al. Undifferentiated headache: broadening the approach to headache in children and adolescents, with supporting evidence from a nationwide school-based cross-sectional survey in Turkey. The journal of headache and pain. 2018;19:1-9. 51. Manandhar K, Risal A, Steiner TJ, Holen A, Linde M. The prevalence of primary headache disorders in Nepal: a nationwide population-based study. The journal of headache and pain. 2015;16(1):1-10. 52. Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJ, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163(2):e293-e309. 53. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):459-80. 54. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache: The Journal of Head and Face Pain. 2018;58(5):700-14. 55. Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Adams AM, et al., editors. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clinic Proceedings; 2016: Elsevier. 56. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache: The Journal of Head and Face Pain. 2012;52(10):1456-70. 57. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache: The Journal of Head and Face Pain. 2005;45:S3-S13. 58. Blumenfeld A, Varon S, Wilcox T, Buse D, Kawata A, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301-15. 59. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache: The Journal of Head and Face Pain. 2015;55:103-22. 60. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-25. 61. ÖZGE A, DOMAÇ S, BAYKAL B, Uludüz D, BELEN H. Başağrısı Bozukluklarının uluslararası sınıflaması. 2021. 62. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain. 1996;119(2):355-61. 63. Petrusic I, Zidverc-Trajkovic J, Podgorac A, Sternic N. Underestimated phenomena: higher cortical dysfunctions during migraine aura. Cephalalgia. 2013;33(10):861-7. 64. Hansen JM, Goadsby PJ, Charles AC. Variability of clinical features in attacks of migraine with aura. Cephalalgia. 2016;36(3):216-24. 65. Karsan N, Prabhakar P, Goadsby P. Characterising the premonitory stage of migraine in children: a clinic-based study of 100 patients in a specialist headache service. The journal of headache and pain. 2016;17:1-7. 66. Calhoun AH, Ford S, Millen C, Finkel AG, Truong Y, Nie Y. The prevalence of neck pain in migraine. Headache: The Journal of Head and Face Pain. 2010;50(8):1273-7. 67. Gori S, Lucchesi C, Baldacci F, Bonuccelli U. Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. Functional neurology. 2015;30(2):119. 68. Silberstein SD. Migraine symptoms: Results of a survey of self‐reported migraineurs. Headache: The Journal of Head and Face Pain. 1995;35(7):387-96. 69. Friedman DI, Evans RW. Are blurred vision and short-duration visual phenomena migraine aura symptoms. Headache. 2017;57(4):643-7. 70. Bigal M, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology. 2008;70(17):1525-33. 71. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine postdrome: an electronic diary study. Neurology. 2016;87(3):309-13. 72. Ducros A. Familial hemiplegic migraine: a model for the genetic studies of migraine. Sage Publications Sage UK: London, England; 2014. p. 1035-7. 73. Society HCCotIH. The international classification of headache disorders, (beta version). Cephalalgia. 2013;33(9):629-808. 74. Goadsby PJ, Holland PR. An Update: Pathophysiology of Migraine. Neurologic clinics. 2019;37(4):651-71. 75. Santoro G, Bernasconi F, Sessa F, Venco A. Premonitory symptoms in migraine without aura: a clinical investigation. Functional neurology. 1990;5(4):339-44. 76. Quintela E, Castillo J, Munoz P, Pascual J. Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia. 2006;26(9):1051-60. 77. Giffin N, Ruggiero L, Lipton RB, Silberstein S, Tvedskov J, Olesen J, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60(6):935-40. 78. Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(1):232-41. 79. Karsan N, Bose P, Goadsby PJ. The migraine premonitory phase. CONTINUUM: Lifelong Learning in Neurology. 2018;24(4):996-1008. 80. Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches: CME. Headache: The Journal of Head and Face Pain. 2007;47(6):951-62. 81. Holland PR, Bartsch T. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28(7):681-2. 82. Martins-Oliveira M, Tavares I, Goadsby PJ. Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. Brain research. 2021;1770:147629. 83. Oliveira M-M, Akerman S, Tavares I, Goadsby PJ. Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. Pain. 2016;157(8):1666. 84. Charbit AR, Akerman S, Goadsby PJ. Dopamine: what's new in migraine? Current opinion in neurology. 2010;23(3):275-81. 85. Charbit AR, Akerman S, Holland PR, Goadsby PJ. Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. Journal of Neuroscience. 2009;29(40):12532-41. 86. Serra G, Collu M, Loddo S, Celasco G, Gessa G. Hypophysectomy prevents yawning and penile erection but not hypomotility induced by apomorphine. Pharmacology Biochemistry and Behavior. 1983;19(6):917-9. 87. Waelkens J. Domperidone in the prevention of complete classical migraine. British Medical Journal (Clinical research ed). 1982;284(6320):944. 88. Burstein R, Jakubowski M. Unitary hypothesis for multiple triggers of the pain and strain of migraine. Journal of comparative neurology. 2005;493(1):9-14. 89. Lampl C, Rudolph M, Deligianni CI, Mitsikostas DD. Neck pain in episodic migraine: premonitory symptom or part of the attack? The journal of headache and pain. 2015;16(1):1-5. 90. Goadsby PJ, Knight YE, Hoskin KL. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain. 1997;73(1):23-8. 91. Johnston MM, Jordan SE, Charles AC. Pain referral patterns of the C1 to C3 nerves: implications for headache disorders. Annals of neurology. 2013;74(1):145-8. 92. Gazerani P, Cairns BE. Dysautonomia in the pathogenesis of migraine. Expert review of neurotherapeutics. 2018;18(2):153-65. 93. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Archives of Neurology & Psychiatry. 1941;46(2):331-9. 94. Leao AA. Spreading depression of activity in the cerebral cortex. Journal of neurophysiology. 1944;7(6):359-90. 95. Hadjikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the national academy of sciences. 2001;98(8):4687-92. 96. Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiological reviews. 2001;81(3):1065-96. 97. Timm FP, Houle TT, Grabitz SD, Lihn A-L, Stokholm JB, Eikermann-Haerter K, et al. Migraine and risk of perioperative ischemic stroke and hospital readmission: hospital based registry study. bmj. 2017;356. 98. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiological reviews. 2017. 99. Bartsch T, Goadsby P. Anatomy and physiology of pain referral patterns in primary and cervicogenic headache disorders. Headache Currents. 2005;2(2):42-8. 100. Weiller C, May A, Limmroth Va, Jüptner M, Kaube H, Schayck R, et al. Brain stem activation in spontaneous human migraine attacks. Nature medicine. 1995;1(7):658-60. 101. Pozo-Rosich P, Storer R, Charbit A, Goadsby P. Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia. 2015;35(14):1298-307. 102. Zhang L, Lu C, Kang L, Li Y, Tang W, Zhao D, et al. Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup. The Journal of Headache and Pain. 2022;23(1):1-11. 103. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. Journal of Neuroscience. 2015;35(17):6619-29. 104. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130(1-2):166-76. 105. Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the trigeminal system in migraine. Headache: The Journal of Head and Face Pain. 2019;59(5):659-81. 106. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179-86. 107. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual review of pharmacology and toxicology. 2015;55:533-52. 108. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron–glia signaling in trigeminal ganglion: implications for migraine pathology. Headache: The Journal of Head and Face Pain. 2007;47(7):1008-23. 109. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews Neurology. 2010;6(10):573-82. 110. Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. Journal of Neuroscience. 2011;31(40):14204-17. 111. Noseda R, Borsook D, Burstein R. Neuropeptides and neurotransmitters that modulate thalamo‐cortical pathways relevant to migraine headache. Headache: The Journal of Head and Face Pain. 2017;57:97-111. 112. Burstein R, Jakubowski M, Garcia‐Nicas E, Kainz V, Bajwa Z, Hargreaves R, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Annals of neurology. 2010;68(1):81-91. 113. Suzuki K, Suzuki S, Shiina T, Kobayashi S, Hirata K. Central sensitization in migraine: a narrative review. Journal of Pain Research. 2022:2673-82. 114. Amin FM, Hougaard A, Magon S, Sprenger T, Wolfram F, Rostrup E, et al. Altered thalamic connectivity during spontaneous attacks of migraine without aura: a resting-state fMRI study. Cephalalgia. 2018;38(7):1237-44. 115. Puledda F, Shields K. Non-pharmacological approaches for migraine. Neurotherapeutics. 2018;15(2):336-45. 116. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1981;9(4):344-52. 117. Barral E, Martins Silva E, García-Azorín D, Viana M, Puledda F. Differential Diagnosis of Visual Phenomena Associated with Migraine: Spotlight on Aura and Visual Snow Syndrome. Diagnostics. 2023;13(2):252. 118. Messina R, Filippi M, Goadsby PJ. Recent advances in headache neuroimaging. Current opinion in neurology. 2018;31(4):379-85. 119. Dobrynina LA, Suslina AD, Gubanova MV, Belopasova AV, Sergeeva AN, Evers S, et al. White matter hyperintensity in different migraine subtypes. Scientific Reports. 2021;11(1):10881. 120. Ahmed SR, Mohamed AAM, Salem HH, Helmy S, Moustafa RR, Borham SMF. Association of white matter hyperintensities with migraine phenotypes and response to treatment. Acta Neurologica Belgica. 2022:1-9. 121. Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. The journal of headache and pain. 2020;21(1):1-16. 122. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache: The Journal of Head and Face Pain. 2006;46(9):1334-43. 123. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology. 2016;12(8):455-64. 124. Torres-Ferrús M, Ursitti F, Alpuente A, Brunello F, Chiappino D, de Vries T, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. The journal of headache and pain. 2020;21(1):1-12. 125. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(2 Suppl):S23-S34. 126. Hipolito Rodrigues M, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018;21(3):256-66. 127. Pakalnis A, editor Migraine and hormones. Seminars in Pediatric Neurology; 2016: Elsevier. 128. Lay CL, Broner SW. Migraine in women. Neurologic clinics. 2009;27(2):503-11. 129. Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Frontiers in neuroscience. 2015;9:37. 130. Ornello R, Caponnetto V, Frattale I, Sacco S. Patterns of migraine in postmenopausal women: a systematic review. Neuropsychiatric Disease and Treatment. 2021;17:859. 131. Nierenburg HdC, Ailani J, Malloy M, Siavoshi S, Hu NN, Yusuf N. Systematic review of preventive and acute treatment of menstrual migraine. Headache: The Journal of Head and Face Pain. 2015;55(8):1052-71. 132. Brandes JL. The influence of estrogen on migraine: a systematic review. Jama. 2006;295(15):1824-30. 133. Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache: The Journal of Head and Face Pain. 2018;58(1):5-21. 134. Lippi G, Mattiuzzi C. Cortisol and migraine: a systematic literature review. Agri. 2017;29(3):95-9. 135. Baksa D, Gecse K, Kumar S, Toth Z, Gal Z, Gonda X, et al. Circadian variation of migraine attack onset: a review of clinical studies. BioMed Research International. 2019;2019. 136. Spanou I, Bougea A, Liakakis G, Rizonaki K, Anagnostou E, Duntas L, et al. Relationship of Migraine and Tension‐Type Headache With Hypothyroidism: A Literature Review. Headache: The Journal of Head and Face Pain. 2019;59(8):1174-86. 137. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640-5. 138. Pavlovic JM, Vieira JR, Lipton RB, Bond DS. Association between obesity and migraine in women. Current pain and headache reports. 2017;21(10):1-6. 139. Peterlin BL, Sacco S, Bernecker C, Scher AI. Adipokines and migraine: a systematic review. Headache: The Journal of Head and Face Pain. 2016;56(4):622-44. 140. Rainero I, Govone F, Gai A, Vacca A, Rubino E. Is migraine primarily a metaboloendocrine disorder? Current pain and headache reports. 2018;22(5):1-9. 141. Hosseinpour M, Maleki F, Khoramdad M, Sullman MJ, Nejadghaderi SA, Kolahi A-A, et al. A systematic literature review of observational studies of the bilateral association between diabetes and migraine. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(3):673-8. 142. Fagernaes C, Heuch I, Zwart JA, Winsvold B, Linde M, Hagen K. Blood pressure as a risk factor for headache and migraine: A prospective population‐based study. European Journal of Neurology. 2015;22(1):156-e11. 143. Scher A, Terwindt G, Picavet H, Verschuren W, Ferrari M, Launer L. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology. 2005;64(4):614-20. 144. Onderwater GL, Ligthart L, Bot M, Demirkan A, Fu J, van der Kallen CJ, et al. Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine. Neurology. 2019;92(16):e1899-e911. 145. Polderman TJ, Benyamin B, De Leeuw CA, Sullivan PF, Van Bochoven A, Visscher PM, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nature genetics. 2015;47(7):702-9. 146. Gormley P, Kurki MI, Hiekkala ME, Veerapen K, Häppölä P, Mitchell AA, et al. Common variant burden contributes to the familial aggregation of migraine in 1,589 families. Neuron. 2018;98(4):743-53. e4. 147. Ophoff RA, Terwindt GM, Vergouwe MN, Van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543-52. 148. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. The Lancet Neurology. 2015;14(1):65-80. 149. Anttila V, Winsvold BS, Gormley P, Kurth T, Bettella F, McMahon G, et al. Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nature genetics. 2013;45(8):912-7. 150. Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature genetics. 2016;48(8):856-66. 151. Eising E, A Datson N, van den Maagdenberg AM, Ferrari MD. Epigenetic mechanisms in migraine: a promising avenue? BMC medicine. 2013;11(1):1-6. 152. Gerring ZF, McRae AF, Montgomery GW, Nyholt DR. Genome-wide DNA methylation profiling in whole blood reveals epigenetic signatures associated with migraine. BMC genomics. 2018;19(1):1-10. 153. Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review. Cephalalgia. 2005;25(3):165-78. 154. Peroutka SJ. What turns on a migraine? A systematic review of migraine precipitating factors. Current pain and headache reports. 2014;18(10):1-6. 155. Dresler T, Caratozzolo S, Guldolf K, Huhn J-I, Loiacono C, Niiberg-Pikksööt T, et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. The journal of headache and pain. 2019;20:1-17. 156. Peterlin BL, Gupta S, Ward TN, MacGregor A. Sex matters: evaluating sex and gender in migraine and headache research. Wiley Online Library; 2011. p. 839-42. 157. Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B, et al. Male and female sex hormones in primary headaches. The journal of Headache and Pain. 2018;19:1-12. 158. Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, et al. Migraine and sleep disorders: a systematic review. The Journal of Headache and Pain. 2020;21(1):1-13. 159. Boardman HF, Thomas E, Millson DS, Croft P. Psychological, sleep, lifestyle, and comorbid associations with headache. Headache: The Journal of Head and Face Pain. 2005;45(6):657-69. 160. Mustelin L, Raevuori A, Kaprio J, Keski‐Rahkonen A. Association between eating disorders and migraine may be explained by major depression. International Journal of Eating Disorders. 2014;47(8):884-7. 161. Razeghi Jahromi S, Ghorbani Z, Martelletti P, Lampl C, Togha M, Federation SoASotEH. Association of diet and headache. The journal of Headache and Pain. 2019;20:1-11. 162. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. Bmj. 2009;339. 163. Lee MJ, Lee C, Chung C-S. The migraine–stroke connection. Journal of stroke. 2016;18(2):146. 164. Alqaqa A. The Association of cardiovascular disease and migraine: review. J Clini Exp Cardiol. 2016;7(8):465. 165. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache: The Journal of Head and Face Pain. 2018;58(4):496-505. 166. Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: a review. Cephalalgia. 2016;36(1):67-91. 167. Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web‐based survey. Headache: The Journal of Head and Face Pain. 2016;56(2):306-22. 168. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. Jama. 2003;290(18):2443-54. 169. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. Journal of the neurological sciences. 2017;372:307-15. 170. Robbins L. Precipitating factors in migraine: a retrospective review of 494 patients. Headache: The Journal of Head and Face Pain. 1994;34(4):214-6. 171. Zhang Q, Shao A, Jiang Z, Tsai H, Liu W. The exploration of mechanisms of comorbidity between migraine and depression. Journal of cellular and molecular medicine. 2019;23(7):4505-13. 172. Kim S-Y, Park S-P. The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. The journal of headache and pain. 2014;15(1):1-8. 173. Beghi E, Bussone G, D’Amico D, Cortelli P, Cevoli S, Manzoni GC, et al. Headache, anxiety and depressive disorders: the HADAS study. The journal of headache and pain. 2010;11:141-50. 174. Samaan Z, Farmer A, Craddock N, Jones L, Korszun A, Owen M, et al. Migraine in recurrent depression: case–control study. The British Journal of Psychiatry. 2009;194(4):350-4. 175. Baskin SM, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache: The Journal of Head and Face Pain. 2006;46:S76-S87. 176. Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatric comorbidities of episodic and chronic migraine. Journal of neurology. 2013;260:1960-9. 177. Mercante JP, Peres MF, Bernik MA. Primary headaches in patients with generalized anxiety disorder. The Journal of Headache and Pain. 2011;12:331-8. 178. Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P. Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. The journal of headache and pain. 2009;10:283-90. 179. Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache: The Journal of Head and Face Pain. 2012;52(1):3-17. 180. Scher A, Stewart W, Ricci J, Lipton R. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106(1-2):81-9. 181. Buse D, Manack A, Serrano D, Turkel C, Lipton R. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. Journal of Neurology, Neurosurgery & Psychiatry. 2010;81(4):428-32. 182. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache: The Journal of Head and Face Pain. 1987;27(2):102-6. 183. Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688-95. 184. He Z, Dong L, Zhang Y, Kong Q, Tan G, Zhou J. Metabolic syndrome in female migraine patients is associated with medication overuse headache: a clinic‐based study in China. European journal of neurology. 2015;22(8):1228-34. 185. Kitamura E, Kanazawa N, Hamada J. Hyperleptinemia increases the susceptibility of the cortex to generate cortical spreading depression. Cephalalgia. 2015;35(4):327-34. 186. Vieira D, Masruha M, Gonçalves A, Zukerman E, Senne Soares C, da Graça Naffah-Mazzacoratti M, et al. Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine. Cephalalgia. 2008;28(6):609-13. 187. De Simone R, Ranieri A. The role of intracranial hypertension in the chronification of migraine. Neurological Sciences. 2015;36:23-8. 188. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, et al. Depression and risk of transformation of episodic to chronic migraine. The journal of headache and pain. 2012;13:615-24. 189. Welch MK, Goadsby PJ. Chronic daily headache: nosology and pathophysiology. Current opinion in neurology. 2002;15(3):287-95. 190. Hovaguimian A, Roth J. Management of chronic migraine. bmj. 2022;379. 191. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: A randomized, placebo‐controlled trial of quality of life and other efficacy measures. Headache: The Journal of Head and Face Pain. 2009;49(8):1153-62. 192. Pascual J, Rivas M, Leira R. Testing the combination beta‐blocker plus topiramate in refractory migraine. Acta neurologica scandinavica. 2007;115(2):81-3. 193. Silberstein S, Dodick D, Lindblad A, Holroyd K, Harrington M, Mathew N, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976-84. 194. Costa C, Tozzi A, Rainero I, Cupini LM, Calabresi P, Ayata C, et al. Cortical spreading depression as a target for anti-migraine agents. The journal of headache and pain. 2013;14(1):1-18. 195. Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. Journal of Clinical Psychiatry. 2008;69(9):1449. 196. Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, et al. CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Current pain and headache reports. 2019;23:1-10. 197. Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. The Journal of Headache and Pain. 2021;22(1):1-9. 198. Tajti J, Szok D, Csáti A, Vécsei L. The pharmacotherapeutic management of episodic and chronic migraine with gepants. Expert Opinion on Pharmacotherapy. 2023;24(8):947-58. 199. Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803. 200. Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-14. 201. Hollanda L, Monteiro L, Melo A. Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. Neurology International. 2014;6(4):5133. 202. Tao H, Wang T, Dong X, Guo Q, Xu H, Wan Q. Effectiveness of transcutaneous electrical nerve stimulation for the treatment of migraine: a meta-analysis of randomized controlled trials. The journal of headache and pain. 2018;19(1):1-10. 203. Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894-904. 204. Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. Jama. 2019;322(19):1887-98. 205. Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ. Pathophysiology of medication overuse headache--an update. Headache. 2014;54(1):204-10. 206. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache: The Journal of head and face pain. 2003;43(3):179-90. 207. Roeckel L-A, Le Coz G-M, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience. 2016;338:160-82. 208. Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M. Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain. 2005;9(3):285-91. 209. Moskowitz MA. The neurobiology of vascular head pain. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1984;16(2):157-68. 210. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system—40 years and counting. The Lancet Neurology. 2019;18(8):795-804. 211. Ma W, Zheng W-H, Kar S, Quirion R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience. 2000;99(3):529-39. 212. Chatchaisak D, Srikiatkhachorn A, Maneesri-le Grand S, Govitrapong P, Chetsawang B. The role of calcitonin gene-related peptide on the increase in transient receptor potential vanilloid-1 levels in trigeminal ganglion and trigeminal nucleus caudalis activation of rat. Journal of chemical neuroanatomy. 2013;47:50-6. 213. Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 2010;30(9):1101-9. 214. Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F. Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia. 2014;34(8):594-604. 215. Wanasuntronwong A, Jansri U, Srikiatkhachorn A. Neural hyperactivity in the amygdala induced by chronic treatment of rats with analgesics may elucidate the mechanisms underlying psychiatric comorbidities associated with medication-overuse headache. BMC neuroscience. 2017;18(1):1-12. 216. Srikiatkhachorn A, Puangniyom S, Govitrapong P. Plasticity of 5‐HT2A serotonin receptor in patients with analgesic‐induced transformed migraine. Headache: The Journal of Head and Face Pain. 1998;38(7):534-9. 217. Ayzenberg I, Obermann M, Leineweber K, Franke L, Yoon MS, Diener HC, et al. Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain. 2008;9(2):109-12. 218. Hagen K, Vatten L, Stovner L, Zwart J, Krokstad S, Bovim G. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia. 2002;22(8):672-9. 219. Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012;13(4):281-90. 220. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies. Pain. 2012;153(1):56-61. 221. Diener H-C, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nature Reviews Neurology. 2016;12(10):575-83. 222. Wang Y-F, Yu C-C, Kuan AS, Chen S-P, Wang S-J. Association between suicidal risks and medication-overuse headache in chronic migraine: a cross-sectional study. The Journal of Headache and Pain. 2021;22(1):36. 223. Cargnin S, Viana M, Sances G, Tassorelli C, Terrazzino S. A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia. 2018;38(7):1361-73. 224. Thorlund K, Sun-Edelstein C, Druyts E, Kanters S, Ebrahim S, Bhambri R, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016;17(1):107. 225. Manzoni GC, Russo M, Taga A, Torelli P. Neurobiology of chronicization. Neurological Sciences. 2017;38(1):81-4. 226. Evers S, Jensen R, European Federation of Neurological S. Treatment of medication overuse headache--guideline of the EFNS headache panel. Eur J Neurol. 2011;18(9):1115-21. 227. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9(4):391-401. 228. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. 2017;377(22):2113-22. 229. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47(5):614-24. 230. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache: The Journal of Head and Face Pain. 2006;46:S182-S91. 231. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. pain. 2011;152(3):S2-S15. 232. Suzuki K, Haruyama Y, Kobashi G, Sairenchi T, Uchiyama K, Yamaguchi S, et al. Central sensitization in neurological, psychiatric, and pain disorders: a multicenter case-controlled study. Pain Research and Management. 2021;2021:1-8. 233. Nijs J, Torres-Cueco R, Van Wilgen P, Lluch Girbés E, Struyf F, Roussel N, et al. Applying modern pain neuroscience in clinical practice: criteria for the classification of central sensitization pain. Pain physician. 2014;17(5):447-57. 234. Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the central sensitization inventory: a systematic review. Pain Practice. 2018;18(4):544-54. 235. Starkweather AR, Heineman A, Storey S, Rubia G, Lyon DE, Greenspan J, et al. Methods to measure peripheral and central sensitization using quantitative sensory testing: A focus on individuals with low back pain. Applied Nursing Research. 2016;29:237-41. 236. Lee MC, Zambreanu L, Menon DK, Tracey I. Identifying brain activity specifically related to the maintenance and perceptual consequence of central sensitization in humans. Journal of Neuroscience. 2008;28(45):11642-9. 237. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature medicine. 2002;8(2):136-42. 238. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2004;55(1):19-26. 239. Fox AW, Davis RL. Migraine chronobiology. Headache: The Journal of Head and Face Pain. 1998;38(6):436-41. 240. Stankewitz A, Aderjan D, Eippert F, May A. Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. Journal of Neuroscience. 2011;31(6):1937-43. 241. Young WB, Richardson ES, Shukla P. Brush allodynia in hospitalized headache patients. Headache: The Journal of Head and Face Pain. 2005;45(8):999-1003. 242. LoPinto C, Young W, Ashkenazi A. Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia. 2006;26(7):852-6. 243. Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, et al. Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arquivos de neuro-psiquiatria. 2017;75:153-9. 244. Schwedt TJ, Krauss MJ, Frey K, Gereau IV RW. Episodic and chronic migraineurs are hypersensitive to thermal stimuli between migraine attacks. Cephalalgia. 2011;31(1):6-12. 245. Maleki N, Szabo E, Becerra L, Moulton E, Scrivani SJ, Burstein R, et al. Ictal and interictal brain activation in episodic migraine: neural basis for extent of allodynia. PloS one. 2021;16(1):e0244320. 246. Delussi M, Vecchio E, Libro G, Quitadamo S, De Tommaso M. Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC neurology. 2020;20:1-12. 247. Guven H, Cilliler AE, Comoglu SS. Cutaneous allodynia in patients with episodic migraine. Neurol Sci. 2013;34(8):1397-402. 248. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs. 2004;18(6):337-42. 249. Levy D, Jakubowski M, Burstein R, editors. Differential effects of sumatriptan on peripheral and central trigeminovascular neurons reveal site of action critical for terminating migraine. Cephalalgia; 2003: BLACKWELL PUBLISHING LTD 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND. 250. Lewis T. Experiments relating to cutaneous hyperalgesia and its spread through somatic nerves. Clin Sci. 1936;2:373-421. 251. LaMotte RH, Shain CN, Simone DA, Tsai E. Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. Journal of neurophysiology. 1991;66(1):190-211. 252. Kilo S, Schmelz M, Koltzenburg M, Handwerker H. Different patterns of hyperalgesia induced by experimental inflammation in human skin. Brain. 1994;117(2):385-96. 253. Coste J, Voisin DL, Luccarini P, Dallel R. A role for wind-up in trigeminal sensory processing: intensity coding of nociceptive stimuli in the rat. Cephalalgia. 2008;28(6):631-9. 254. Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Progress in neurobiology. 2000;61(2):169-203. 255. Aspinall SL, Leboeuf-Yde C, Etherington SJ, Walker BF. Feasibility of using the Neuropen for temporal summation testing. Pain Manag. 2019;9(4):361-8. 256. Beck AT, Ward C, Mendelson M, Mock J, Erbaugh J. Beck depression inventory (BDI). Arch Gen Psychiatry. 1961;4(6):561-71. 257. Ulusoy M, Sahin NH, Erkmen H. The Beck anxiety inventory: psychometric properties. J Cogn Psychother. 1998;12(2):163-72. 258. Ertas M, Siva A, Dalkara T, Uzuner N, Dora B, Inan L, et al. Validity and reliability of the Turkish Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2004;44(8):786-93. 259. Gedikoglu U, Coskun O, Inan LE, Ucler S, Tunc T, Emre U. Validity and reliability of Turkish translation of Migraine Disability Assessment (MIDAS) questionnaire in patients with migraine. Cephalalgia. 2005;25(6):452-6. 260. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999;53(5):988-. 261. yalin. Identification of Allodynic Migraine Patients with the Turkish Version of the Allodynia Symptom Checklist: Reliability and Consistency Study. 262. Florencio LL, Chaves TC, Branisso LB, Gonçalves MC, Dach F, Speciali JG, et al. 12 item Allodynia Symptom Checklist/Brasil: cross-cultural adaptation, internal consistency and reproducibility. Arquivos de neuro-psiquiatria. 2012;70:852-6. 263. Rolke R, Baron R, Maier Ca, Tölle T, Treede R-D, Beyer A, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006;123(3):231-43. 264. Maxwell S, Sterling M. An investigation of the use of a numeric pain rating scale with ice application to the neck to determine cold hyperalgesia. Manual therapy. 2013;18(2):172-4. 265. Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J. Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. The journal of headache and pain. 2011;12(2):157-72. 266. Atasoy HT, Unal AE, Atasoy N, Emre U, Sumer M. Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache: The Journal of Head and Face Pain. 2005;45(1):25-31. 267. Vetvik KG, MacGregor EA, Lundqvist C, Russell MB. Prevalence of menstrual migraine: a population-based study. Cephalalgia. 2014;34(4):280-8. 268. MacGregor A. Migraine associated with menstruation. Functional neurology. 2000;15:143-53. 269. Wang Y-F, Wang S-J. Hypertension and migraine: Time to revisit the evidence. Current Pain and Headache Reports. 2021;25:1-9. 270. Rist PM, Winter AC, Buring JE, Sesso HD, Kurth T. Migraine and the risk of incident hypertension among women. Cephalalgia. 2018;38(12):1817-24. 271. Agostoni E, Aliprandi A. Migraine and hypertension. Neurological Sciences. 2008;29:37-9. 272. Dominguez C, Vieites-Prado A, Perez-Mato M, Sobrino T, Rodriguez-Osorio X, Lopez A, et al. Role of adipocytokines in the pathophysiology of migraine: a cross-sectional study. Cephalalgia. 2018;38(5):904-11. 273. Weiss HD, Stern BJ, Goldberg J. Post‐traumatic migraine: chronic migraine precipitated by minor head or neck trauma. Headache: The Journal of Head and Face Pain. 1991;31(7):451-6. 274. Bennett DR, Fuenning SI, Sullivan G, Weber J. Migraine precipitated by head trauma in athletes. The American Journal of Sports Medicine. 1980;8(3):202-5. 275. Raggi A, Grazzi L, Grignani E, Leonardi M, Sansone E, Scaratti C, et al. The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it? Neurol Sci. 2018;39(Suppl 1):125-7. 276. Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology. 2004;62(8):1338-42. 277. Kristoffersen ES, Grande RB, Aaseth K, Lundqvist C, Russell MB. Management of primary chronic headache in the general population: the Akershus study of chronic headache. The journal of headache and pain. 2012;13(2):113-20. 278. Scher A, Lipton R, Stewart W, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321-8. 279. Siva ZO, Uluduz D, Keskin FE, Erenler F, Balcı H, Uygunoğlu U, et al. Determinants of glucose metabolism and the role of NPY in the progression of insulin resistance in chronic migraine. Cephalalgia. 2018;38(11):1773-81. 280. Fava A, Pirritano D, Consoli D, Plastino M, Casalinuovo F, Cristofaro S, et al. Chronic migraine in women is associated with insulin resistance: a cross‐sectional study. European journal of neurology. 2014;21(2):267-72. 281. Munir A, Akbar M. Serum Bilirubin and G-Glutamyl Transferase in Female Patients Suffering from Migraine. National Editorial Advisory Board. 2020;31(12):110. 282. Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davì G, et al. Correlation between migraine severity and cholesterol levels. Pain Practice. 2015;15(7):662-70. 283. Tayyebi A, Poursadeghfard M, Nazeri M, Pousadeghfard T. Is there any correlation between migraine attacks and iron deficiency anemia? A case-control study. International journal of hematology-oncology and stem cell research. 2019;13(3):164. 284. Pamuk GE, Top MŞ, Uyanık MŞ, Köker H, Akker M, Ak R, et al. Is iron-deficiency anemia associated with migraine? Is there a role for anxiety and depression? Wiener klinische Wochenschrift. 2016;128:576-80. 285. Swartz RH, Kern RZ. Migraine is associated with magnetic resonance imaging white matter abnormalities: a meta-analysis. Archives of neurology. 2004;61(9):1366-8. 286. Schur EA, Noonan C, Buchwald D, Goldberg J, Afari N. A twin study of depression and migraine: evidence for a shared genetic vulnerability. Headache: The Journal of Head and Face Pain. 2009;49(10):1493-502. 287. Lipton RB, Hamelsky SW, Kolodner KB, Steiner T, Stewart WF. Migraine, quality of life, and depression: a population-based case–control study. Neurology. 2000;55(5):629-35. 288. Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky D. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain. 2003;104(3):693-700. 289. Guy N, Marques AR, Orliaguet T, Lanteri-Minet M, Dallel R, Clavelou P. Are there differences between cephalic and extracephalic cutaneous allodynia in migraine patients? Cephalalgia. 2010;30(7):881-6. 290. Di Antonio S, Castaldo M, Ponzano M, Bovis F, Hugo Villafañe J, Torelli P, et al. Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine. Headache: The Journal of Head and Face Pain. 2022;62(2):176-90. 291. Cooke L, Eliasziw M, Becker WJ. Cutaneous allodynia in transformed migraine patients. Headache: The Journal of Head and Face Pain. 2007;47(4):531-9. 292. Kitaj MB, Klink M. Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache: The Journal of Head and Face Pain. 2005;45(8):992-8. 293. Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache. Archives of neurology. 1996;53(4):373-6. 294. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain. 2001;93(1):7-14. 295. Ashina S, Melo-Carrillo A, Szabo E, Borsook D, Burstein R. Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202). Cephalalgia. 2023;43(3):03331024221147881. 296. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology. 2004;63(5):848-52.tr_TR
dc.identifier.urihttps://hdl.handle.net/11655/33876
dc.description.abstractHypersensitivity to non-noxious stimulus is reported in migraine patients during acute attacks. We aimed to assess the demographical, clinical and headache characteristics, the comorbidities,the pain sensitivity characteristics and chronicity-related factors in medication overuse headache patients with chronic migraine (MOH+CM) compared to the episodic migraineurs (EM) and healthy control (HC). Adult participants were prospectively enrolled in 3 groups. Demographical features, clinical, laboratory and neuroimaging findings, MIDAS, 12-item Allodynia Symptom Checklist-12 (ASC-12), Beck Depression and Anxiety Inventory scores were recorded. To quantify the type of pain sensitivity and spatial characteristics of central sensitization; pinprick hyperalgesia, brush allodynia, cold allodynia, and temporal summation tests were applied to cephalic (left forehead region) and extra-cephalic (left forearm anterior surface) regions. Comparisons among the groups were analyzed. A total of 90 participants (30 in each group) were enrolled to the study. Age and sex (female dominance) did not differ among the groups. The MOH+CM patients revealed higher BMI, fasting glucose, total cholesterol levels, and lower iron binding capacity compared to the HC. The migraine disease history, attack duration, frequency, severity, triptan usage, combination analgesic usage, the MIDAS, Beck Depression and Anxiety, ASC-12 scores were statistically significant and high in MOH+CM compared to the EM. All of the MOH+CM patients reported that they felt a compulsion to take their pain killers regularly for their attacks and the possibility of missing a dose made them anxious or disturbed. The 70% MOH+CM patients wished they could stop taking their painkillers and knew that painkillers could harm. On sensory examinations, MOH+CM and EM patients disclosed both cephalic and extra-cephalic cold allodynia (statistically significant high scores in MOH+CM compared to EM and HC).The pinprick hyperalgesia and temporal summation were detected at cephalic region in both group migraineurs and statistically significant high scores in the MOH+CM compared to EM and HC groups. Among the ASC-12 items, combing hair, wearing eyeglasses, wearing contact lenses, wearing a necklace, tight clothing, resting the face or head on a pillow, exposure to heat (e.g., cooking, washing your face with hot water) and exposure to cold (e.g., using an ice pack, washing your face with cold water) were correlated with pain sensitivity sensory examination modalities. Pain sensitivity examinations provide qualitative and quantitative findings for understanding the pathophysiology of headache. The MOH+CM patients revealed metabolic syndrome, depressive features, severe disability, and prominent cephalic and extra-cephalic pain hypersensitivity. The pain hypersensitivity is associated with chronicity and higher levels of disability. Pain modulation systems are prominently altered in MOH+CM compared to EM and HC. Identification of chronicity-related factors and quantification of central sensitization, may provide insight into pathogenesis and personalized treatment options in chronic headache patients.tr_TR
dc.language.isoturtr_TR
dc.publisherTıp Fakültesitr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectkronik migren, epizodik migren, allodini, hiperaljezi, ağrı duyarlılığı, engelliliktr_TR
dc.subject.lcshSinir sistemitr_TR
dc.titleİLAÇ AŞIRI KULLANIM BAŞAĞRISINDA BELİRLEYİCİ ÖZELLİKLER VE AĞRI DUYARLILIĞININ DEĞERLENDİRİLMESİtr_TR
dc.typeinfo:eu-repo/semantics/masterThesistr_TR
dc.description.ozetMigren hastalarında, akut migren atağı esnasında, normalde ağrı cevabı oluşturmayan uyaranlara karşı aşırı duyarlılık bildirilmektedir. Bu çalışmada, kronik migren ve ilaç aşırı kullanım başağrısı olan hastalarda (İAKB+KM) demografik, klinik ve başağrısı özellikleri, eşlik eden hastalıklar, ağrı duyarlılığı özellikleri ve kronikleşme ile ilişkili risk faktörleri, epizodik migrenli (EM) ve sağlıklı kontrol (K) gruplarıyla karşılaştırarak değerlendirilmesi amaçlanmıştır. Yetişkin katılımcılar, prospektif olarak 3 farklı gruba dahil edilmiştir. Demografik özellikler, klinik, laboratuvar ve nörogörüntüleme bulguları, MIDAS, Allodini Semptom Kontrol Listesi (ASC-12), Beck Depresyon ve Anksiyete Envanteri skorları kaydedilmiştir. Ağrı duyarlılığı tipi ve santral sensitizasyon uzaysal özelliklerini nicelendirmek için çeşitli duyusal testler (pinprick hiperaljezi, fırça allodinisi, soğuk allodinisi ve temporal sumasyon) sefalik (sol alın) ve ekstra-sefalik (sol ön kol anterior) bölgelere uygulanmıştır. Gruplar arasındaki farklılıklar ve risk faktörleri analiz edilmiştir. Çalışmaya toplamda 90 katılımcı (her grupta 30 kişi) dahil edilmiştir. Yaş ve cinsiyet (kadın hakimiyeti) açısından gruplar arasında farklılık saptanmamıştır. İAKB+KM hastalarında, K grubuna kıyasla daha yüksek BMI, açlık kan şekeri, total kolesterol ve daha düşük demir bağlama kapasitesi düzeyleri gözlenmiştir. İAKB+KM hastalarında migren hastalık öyküsü, atak süresi, sıklığı, şiddeti, triptan kullanımı, kombine analjezik kullanımı, MIDAS, Beck Depresyon ve Anksiyete, ASC-12 skorları EM'ye kıyasla istatistiksel olarak anlamlı ve yüksek bulunmuştur. Tüm İAKB+KM hastaları, atakları için düzenli olarak ağrı kesicilerini almak zorunda olduklarını ve bir dozu kaçırma olasılığının onları endişeli veya rahatsız ettiğini belirtmişlerdir. İAKB+KM grubundaki %70 hasta, ağrı kesicileri almayı bırakabilmiş olmayı istediklerini ve ağrı kesicilerinin zararlı olabileceğini bildiklerini ifade etmişlerdir. Duyusal muayenelerde, İAKB+KM ve EM hastalarında hem sefalik hem de ekstra-sefalik bölgede soğuk allodini saptanmıştır. İAKB+KM 'de EM ve K’e kıyasla istatistiksel olarak anlamlı ve daha yüksek skorlar bildirilmiştir. Pinprick hiperaljezisi ve temporal sumasyon her iki grup migrenli hastada sefalik bölgede tespit edilmiş ve İAKB+KM grubunda EM ve K gruplarına kıyasla istatistiksel olarak daha yüksek skorlar bildirilmiştir. ASC-12 anketinde saç tararken, gözlük takarken, lens takarken, kolye takarken, dar kıyafetler giyerken, yüzünü veya başını yastığa koyarken, sıcak (örneğin, pişirme, sıcak suyla yüz yıkama) ve soğuk (örneğin, buz torbası kullanma, soğuk suyla yüz yıkama) maruziyetinin, ağrı hassasiyeti duyusal muayene modaliteleriyle ilişkili olduğu bulunmuştur. Ağrı duyarlılığı muayeneleri, başağrısının patofizyolojisini anlama açısından kalitatif ve kantitatif bulgular sunmaktadır. İAKB+KM hastalarında metabolik sendrom, depresif özellikler, ciddi engellilik ve belirgin sefalik ve ekstra-sefalik ağrı duyarlılığı saptanmıştır. Ağrı duyarlılığının, kronikleşme ve daha yüksek engellilik düzeyleri ile ilişkili olduğu saptanmıştır. Ağrı modülasyon sistemleri, İAKB+KM hastalarında EM ve K gruplarına kıyasla belirgin şekilde değişmiştir. Kronikleşme-ilişkili risk faktörlerin belirlenmesi ve santral duyarlılaşmanın nicelendirilmesinin, kronik başağrısı hastalarında patogeneze ışık tutması yanında kişiselleştirilmiş tedavi seçeneklerini belirlemede de değerli olacağını düşündürmektedir.tr_TR
dc.contributor.departmentNörolojitr_TR
dc.embargo.terms6 aytr_TR
dc.embargo.lift2024-02-06T11:34:59Z
dc.fundingYoktr_TR
dc.subtypemedicineThesistr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster